The androgen receptor (AR) is involved in the development, growth and progression of
prostate cancer 1 (CaP). CaP often progresses from an androgen-dependent to an androgen-…

Individual cancers harbor a set of genetic aberrations that can be informative for identifying
rational therapies currently available or in clinical trials. We implemented a pilot study to …

Background : Nuclear accumulation of p53 protein has been shown to be strongly associated
with missense p53 mutations. Studies of nuclear accumulation of p53 protein in prostate …

Recurrent fusions of ETS genes are considered driving mutations in a diverse array of cancers,
including Ewing's sarcoma, acute myeloid leukemia, and prostate cancer. We investigate …

The switch/sucrose non-fermentable (SWI/SNF) complex has a crucial role in chromatin
remodelling 1 and is altered in over 20% of cancers 2 , 3 . Here we developed a proteolysis-…

Human prostate cancer cell lines are particularly difficult to establish, and most existing cell
lines do not exhibit features commonly seen in human prostate cancer. Most available …

Prostate cancer antigen 3 (PCA3) is the most specific prostate cancer biomarker but its
function remains unknown. Here we identify PRUNE2, a target protein-coding gene variant, …

Impairment of double-stranded DNA break (DSB) repair is essential to many cancers.
However, although mutations in DSB repair proteins are common in hereditary cancers, …

BACKGROUND Recent evidence indicates that cancer stem cells play an important role in
tumor initiation and maintenance. Additionally, the effect of tissue‐resident stem cells located …

Synthetic lethality and collateral lethality are two well-validated conceptual strategies for
identifying therapeutic targets in cancers with tumour-suppressor gene deletions 1 , 2 , 3 . Here, …